Every Form 4 that Cigna Group (CI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CI filings page.
Cigna Group (CI) reported that executive vice president and special advisor to the CEO Everett Neville sold 617 shares of common stock on September 3, 2026 in an open-market or private transaction at $284.05 per share, pursuant to a Rule 10b5-1 trading plan adopted on June 2, 2026. Following this sale, he directly holds 5,053 shares of Cigna Group common stock.
Cigna Group (CI) reports that President and Chief Executive Officer Brian C. Evanko received equity awards on September 1, 2026. He was granted 6,716 stock options with an exercise price of $281.1325 per share and a separate award of 3,113 restricted shares, both vesting in three equal annual installments beginning September 1, 2027. Following these grants, he holds 41,030 common shares directly, plus indirect holdings of 25,614 shares through a GRAT and 919.5791 shares through Cigna’s 401(k) Plan. No Rule 10b5-1 trading plan is reported.
Cigna Group (CI) director George Kurian reported an acquisition of 108.6642 phantom stock units on August 31, 2026 under the company’s director Deferral Plan, increasing his directly held phantom stock balance to 2,041.8523 units. These units represent voluntary deferral of a portion of his cash retainer into a hypothetical stock fund and are economically equivalent to Cigna common shares but will be settled in cash.
Cigna Group (CI) reported that executive Bryan Holgerson received small additional awards of phantom stock units linked to Cigna common stock. On 2026-07-09, 2026-07-23, and 2026-08-06 he acquired 0.8873, 0.9458, and 0.9837 units, respectively, under the Executive Deferred Compensation Plan, which are economically equivalent to CI shares but will be settled in cash. He also reports indirect ownership of 735.9274 CI common shares held through The Cigna Group's 401(k) Plan.
Cigna Group (CI) executive Nicole S. Jones, EVP, Chief Administrative Officer and Chief Human Resources Officer, reported selling 2,677 shares of common stock on 2026-08-18 at $279.61 per share in an open-market transaction pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. After this sale, she directly holds 25,880 shares and indirectly holds 1,451.2364 shares through participation in The Cigna Group's 401(k) Plan.
The Cigna Group executive Nicole S. Jones, EVP and Chief Administrative and Chief Human Resources Officer, exercised 15,346 employee stock options at $192.02 per share on August 4–5, 2026, receiving common stock.
She also sold 19,436 common shares at $276.27 per share on August 4, 2026. All trades were made under a Rule 10b5-1 trading plan adopted May 4, 2026. As of August 4, 2026, she reported 1,451.2364 shares held indirectly through The Cigna Group's 401(k) Plan.
Cigna Group Chief Accounting Officer Jamie G. Kates exercised employee stock options for 899 shares of common stock at $152.8947 per share and, on the same date, sold 899 shares in an open-market transaction at $298.612 per share. Following these transactions, Kates directly holds 2,368 Cigna common shares. The exercised option was originally granted on February 28, 2018 and vested in three equal annual installments beginning February 28, 2019.
Cigna Group executive Durga Prasad Koka, EVP and Global CIO, reported a routine tax-related share disposition. On the vesting of restricted shares, 729 common shares were withheld to cover tax obligations at an indicated value of $275.53 per share. After this withholding, Koka directly holds 6,552 Cigna common shares. This was not an open-market sale, but an automatic mechanism tied to equity compensation.
Kurian George reported acquisition or exercise transactions in this Form 4 filing.
The Cigna Group director George Kurian received 108.1471 Phantom Stock Units on May 29, 2026 as a grant under the company’s director deferred compensation plan. These units reflect a voluntary deferral of his cash retainer at $277.40 per unit and are economically equivalent to common shares but will be settled in cash. Following this award and related dividend reinvestments, he holds a total of 1,922.4494 phantom stock units linked to Cigna common stock.
The Cigna Group’s Chairman and CEO David Cordani exercised employee stock options and sold shares in a pre-planned series of transactions. On May 12–13, 2026, he exercised options covering 212,543 shares of common stock at exercise prices of $149.135 and $197.35 per share, converting them into common shares.
Over the same period, he conducted open-market sales totaling 201,878 shares of common stock at weighted average prices generally between about $286 and $299 per share, according to price ranges in the filing. These sales were made under a Rule 10b5-1 trading plan adopted on February 6, 2026, meaning they were pre-arranged rather than opportunistic.
After these transactions, Cordani directly owned 57,766 shares of Cigna Group common stock. The filing also lists additional indirect holdings, including shares held through a 401(k) plan, a trust, and a GRAT, which are separate from his direct position.
Cigna Group director Eric J. Foss received a grant of 782 shares of common stock on April 22, 2026. The shares were acquired at no cost as a compensation-related award and are held directly. Following this grant, Foss directly owns 36,696 shares of Cigna common stock.
McClellan Mark B. reported acquisition or exercise transactions in this Form 4 filing.
Cigna Group director Mark B. McClellan received a grant of 782 shares of common stock. The award was recorded at a price of $0.0000 per share, reflecting stock-based compensation rather than a market purchase. Following this grant, he directly holds 6,891 Cigna common shares.
Hathi Neesha reported acquisition or exercise transactions in this Form 4 filing.
Cigna Group director Neesha Hathi received a grant of 782 shares of common stock as compensation. The shares were awarded at a stated price of $0.0000 per share, indicating a non-cash grant rather than an open-market purchase. Following this award, Hathi directly holds 4,151 Cigna Group shares.
ZARCONE DONNA F reported acquisition or exercise transactions in this Form 4 filing.
Cigna Group director Donna F. Zarcone received an award of 782 shares of common stock on April 22, 2026. The grant was compensation-related, with no purchase price per share reported. Following this award, her directly owned holdings increased to 27,517 shares of Cigna common stock.
Her overall economic interest also includes cash-settled hypothetical shares tied to Cigna’s stock value, which are not shown in the share table because they are paid in cash rather than stock upon separation from service.
MAZZARELLA KATHLEEN M reported acquisition or exercise transactions in this Form 4 filing.
Cigna Group director Kathleen M. Mazzarella received an equity grant of 782 shares of Cigna common stock. The award was recorded at a price of $0.00 per share, indicating it was a compensation-related grant rather than a market purchase. After this grant, she directly holds 6,891 Cigna shares.
Kurian George reported acquisition or exercise transactions in this Form 4 filing.
Cigna Group director George Kurian received an award of 782 shares of common stock on April 22, 2026. The shares were granted at $0.00 per share, increasing his directly held position to 4,560 shares of Cigna Group common stock.
A footnote explains that his economic interest also includes hypothetical shares whose value is tied to Cigna Group stock but settled in cash upon separation from service, so these cash-settled units are not included in the reported share totals.
Ross Kimberly A. reported acquisition or exercise transactions in this Form 4 filing.
Cigna Group director Kimberly A. Ross received a stock award of 782 shares of Common Stock on April 22, 2026. The shares were granted at no stated purchase price, reflecting compensation rather than a market purchase.
After this award, Ross directly owns 5,294 shares of Cigna Group Common Stock.
Cigna Group director Michael J. Hennigan received a grant of 782 shares of Common Stock on April 22, 2026. The shares were acquired as a compensation-related grant or award at a stated price of $0.0000 per share. Following this transaction, he directly holds 1,350 shares of Cigna Group common stock.
Cigna Group director Philip Ozuah received a stock award that increased his direct ownership. On April 22, 2026, he acquired 782 shares of Cigna common stock through a grant/award acquisition at a stated price of $0.00 per share. After this award, his directly held position rose to 2,583 common shares. This appears to be a routine equity compensation grant rather than an open-market purchase or sale.
WISEMAN ERIC C reported acquisition or exercise transactions in this Form 4 filing.
Cigna Group director Eric C. Wiseman received an equity award of 782 shares of common stock, recorded at a price of $0.00 per share as a compensation grant. Following this award, he directly holds 23,940 common shares. The filing notes that his economic interest also includes cash-settled hypothetical shares tied to Cigna’s stock value, which are not counted in the reported share totals.
Cigna Group Chief Accounting Officer Jamie G. Kates reported equity compensation changes. On February 27, 2026, Kates was granted 657 employee stock options and additional shares of common stock as part of strategic performance share settlements and new restricted share awards. The options and restricted shares vest in three equal annual installments beginning March 1, 2027. A total of 71 and 61 shares of common stock were withheld to satisfy tax obligations tied to these awards, leaving Kates with 2,368 common shares directly owned.
Cigna Group executive Durga Prasad Koka reported new equity awards and related tax share withholdings. On February 27, 2026, he was granted an employee stock option for 4,127 shares at a price of $0.00 per share, which vests in three equal annual installments beginning March 1, 2027. He also acquired common stock through settlement of strategic performance shares for the 2023–2025 period and through restricted share grants, with vesting for certain restricted shares also starting March 1, 2027. Separate transactions show small blocks of common stock withheld at $287.55 per share to cover tax obligations on these equity awards, rather than open-market sales.
Cigna Group executive Neville Everett reported several equity transactions involving company stock. On March 2, he completed an open-market sale of 1,719 common shares at a price of $288.91 per share under a pre-arranged Rule 10b5-1 trading plan adopted on May 22, 2025.
On February 27, he received equity awards tied to company performance and compensation programs, including 2,602 and 2,678 common shares granted at no cost and 4,127 employee stock options that vest in three equal annual installments beginning March 1, 2027. Some common shares (883 and 517) were withheld to cover tax obligations upon settlement of strategic performance shares and vesting of restricted shares.
Cigna Group executive Nicole S. Jones reported a mix of stock transactions. She sold 2,307 shares of common stock at $288.91 per share in an open-market sale executed under a Rule 10b5-1 trading plan adopted on May 8, 2025.
Earlier on February 27, 2026, she received 8,066 employee stock options and 9,367 shares of common stock through equity awards and performance share settlement at no cash cost. On the same date, 2,738 shares were withheld to cover tax obligations tied to those awards.
After these transactions, she directly held 32,647 shares of Cigna common stock and 8,066 stock options, and indirectly held 1,434.7897 shares through participation in The Cigna Group’s 401(k) Plan.
Cigna Group executive Brian C. Evanko reported multiple equity compensation transactions. He received an employee stock option for 15,082 shares and two grants of common stock for 6,428 and 9,787 shares on February 27, 2026, tied to strategic performance shares and restricted stock awards.
The filing also shows dispositions of 2,979 and 1,788 common shares at $287.55 per share, which were withheld to satisfy tax obligations rather than open-market sales. Evanko additionally reports indirect holdings of common stock through a grantor retained annuity trust and The Cigna Group’s 401(k) plan.
Cigna Group EVP and CFO Ann M. Dennison reported equity compensation changes involving company stock. She received an award of 8,066 employee stock options with an exercise price of $0.0000, which vest in three equal annual installments beginning on March 1, 2027. She was also granted 5,234 shares of common stock as restricted shares that vest in three equal annual installments beginning on March 1, 2027. To satisfy tax obligations upon the vesting of restricted shares, 409 shares of common stock were disposed of at $287.55 per share through share withholding, leaving her with 7,745 common shares held directly.
The Cigna Group Chairman & CEO David Cordani reported new equity awards and related tax withholdings. He was granted 37,516 employee stock options at an exercise price of $0, vesting in three equal annual installments beginning March 1, 2027.
He also acquired 23,788 shares of common stock from settlement of strategic performance shares for the 2023–2025 period and 17,389 restricted shares that vest in three equal annual installments beginning March 1, 2027. To cover tax obligations on these awards, 11,024 and 4,408 shares were disposed of at $287.55 per share. The filing also lists indirect holdings in common stock through a trust, a GRAT, and ongoing participation in The Cigna Group's 401(k) Plan.
The Cigna Group director George Kurian increased his deferred compensation stake through a grant of phantom stock units. On this Form 4, he acquired 103.5125 phantom stock units on February 27, 2026 as a grant, bringing his total phantom stock unit holdings to 1,803.6672.
The units reflect a voluntary deferral of a portion of his cash retainer into a hypothetical stock fund under Cigna’s Deferred Compensation Plan of 2005 for directors. Each phantom stock unit is the economic equivalent of one share of Cigna common stock and will be settled in cash. The total includes 9.3181 phantom stock units credited through a dividend reinvestment feature of the plan.
The Cigna Group director reports a routine deferred compensation transaction. On 11/28/2025, the director converted part of a cash retainer into 108.1939 phantom stock units under Cigna’s Deferred Compensation Plan of 2005 for Directors. Each phantom stock unit is the economic equivalent of one share of The Cigna Group’s common stock and will be settled in cash rather than stock.
After this transaction, the director beneficially owns 1,690.8366 phantom stock units, which includes 8.0936 units acquired through the plan’s dividend reinvestment feature. This filing reflects compensation deferral choices rather than an open‑market trade in Cigna common shares.
The Cigna Group (CI) Chairman & CEO and director reported an open‑market purchase of 4,134 shares on 11/03/2025 at a weighted average price of $241.8762, with individual prices ranging from $241.876 to $241.97.
Following the transaction, beneficial ownership stands at 21,356 shares held directly; 157,935 shares held indirectly by trust; 440,798 shares held indirectly by a grantor retained annuity trust; and 1,782.7866 shares held indirectly via the 401(k) plan.
Brian C. Evanko, President and Chief Operating Officer, reported option exercises and open-market sales of Common Stock of Cigna Group (CI) under a Rule 10b5-1 plan. On 10/03/2025 he exercised 5,368 employee stock options at an exercise price of $139.22 and sold 5,368 shares at a reported price of $300. On 10/06/2025 he exercised an additional 901 options at $139.22. The filing shows beneficial ownership following the transactions of 52,083 shares (direct) plus 904.1848 shares held indirectly in the company 401(k).
The transactions were effected under a 10b5-1 trading plan adopted on 05/07/2025. The option grants referenced were originally issued on 03/01/2016 with vesting in three equal annual installments; the options expire on 03/01/2026 as stated.